BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 33725886)

  • 21. M6A-related bioinformatics analysis reveals that HNRNPC facilitates progression of OSCC via EMT.
    Huang GZ; Wu QQ; Zheng ZN; Shao TR; Chen YC; Zeng WS; Lv XZ
    Aging (Albany NY); 2020 Jun; 12(12):11667-11684. PubMed ID: 32526707
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Prognostic Value of m6A RNA Methylation Regulators in Colon Adenocarcinoma.
    Liu T; Li C; Jin L; Li C; Wang L
    Med Sci Monit; 2019 Dec; 25():9435-9445. PubMed ID: 31823961
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The N6-Methyladenosine- (m6A-) Associated Genes Act as Strong Key Biomarkers for the Prognosis of Pancreatic Adenocarcinoma.
    Li F; Zhang P
    Comput Math Methods Med; 2021; 2021():8715823. PubMed ID: 34840598
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic risk signature based on the expression of three m6A RNA methylation regulatory genes in kidney renal papillary cell carcinoma.
    Sun Z; Jing C; Xiao C; Li T; Wang Y
    Aging (Albany NY); 2020 Nov; 12(21):22078-22094. PubMed ID: 33177247
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Elucidating the clinical and immunological value of m6A regulator-mediated methylation modification patterns in adrenocortical carcinoma.
    Xu W; Li H; Hameed Y; Abdel-Maksoud MA; Almutairi SM; Mubarak A; Aufy M; Alturaiki W; Alshalani AJ; Mahmoud AM; Li C
    Oncol Res; 2023; 31(5):819-831. PubMed ID: 37547754
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multiple m
    Qu N; Qin S; Zhang X; Bo X; Liu Z; Tan C; Wen G; Jiang H
    BMC Cancer; 2020 Feb; 20(1):165. PubMed ID: 32111180
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of an eight-m6A RNA methylation regulator prognostic signature of uterine corpus endometrial carcinoma based on bioinformatics analysis.
    Miao C; Fang X; Chen Y; Zhao Y; Guo Q
    Medicine (Baltimore); 2021 Dec; 100(49):e27689. PubMed ID: 34889221
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of an m6A-Related Signature as Biomarker for Hepatocellular Carcinoma Prognosis and Correlates with Sorafenib and Anti-PD-1 Immunotherapy Treatment Response.
    Jiang H; Ning G; Wang Y; Lv W
    Dis Markers; 2021; 2021():5576683. PubMed ID: 34221187
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A five-gene signature derived from m6A regulators to improve prognosis prediction of neuroblastoma.
    Wang Z; Cheng H; Xu H; Yu X; Sui D
    Cancer Biomark; 2020; 28(3):275-284. PubMed ID: 32176634
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Over expression of DNA damage and cell cycle dependent proteins are associated with poor survival in patients with adrenocortical carcinoma.
    Subramanian C; Cohen MS
    Surgery; 2019 Jan; 165(1):202-210. PubMed ID: 30413320
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Construction of a robust prognostic model for adult adrenocortical carcinoma: Results from bioinformatics and real-world data.
    Tian X; Xu WH; Anwaier A; Wang HK; Wan FN; Cao DL; Luo WJ; Shi GH; Qu YY; Zhang HL; Ye DW
    J Cell Mol Med; 2021 Apr; 25(8):3898-3911. PubMed ID: 33626208
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The methylation modification of m6A regulators contributes to the prognosis of ovarian cancer.
    Zhu W; Zhao L; Kong B; Liu Y; Zou X; Han T; Shi Y
    Ann Transl Med; 2022 Jan; 10(2):59. PubMed ID: 35282121
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune signature of T follicular helper cells predicts clinical prognostic and therapeutic impact in lung squamous cell carcinoma.
    Xu F; Zhang H; Chen J; Lin L; Chen Y
    Int Immunopharmacol; 2020 Apr; 81():105932. PubMed ID: 31836430
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of an immune-related gene signature as a prognostic target and the immune microenvironment for adrenocortical carcinoma.
    Xu C; Qin C; Jian J; Peng Y; Wang X; Chen X; Wu D; Song Y
    Immun Inflamm Dis; 2022 Sep; 10(9):e680. PubMed ID: 36039643
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potential role of m6A RNA methylation regulators in osteosarcoma and its clinical prognostic value.
    Liu H; Qin G; Ji Y; Wang X; Bao H; Guan X; Wei A; Cai Z
    J Orthop Surg Res; 2021 May; 16(1):294. PubMed ID: 33952279
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of FSCN1 and FOXM1 are associated with poor prognosis of adrenocortical carcinoma patients.
    Liang J; Liu Z; Wei X; Zhou L; Tang Y; Zhou C; Wu K; Zhang F; Zhang F; Lu Y; Zhu Y
    BMC Cancer; 2019 Nov; 19(1):1165. PubMed ID: 31783819
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dysregulated N6-methyladenosine methylation writer METTL3 contributes to the proliferation and migration of gastric cancer.
    Liu T; Yang S; Sui J; Xu SY; Cheng YP; Shen B; Zhang Y; Zhang XM; Yin LH; Pu YP; Liang GY
    J Cell Physiol; 2020 Jan; 235(1):548-562. PubMed ID: 31232471
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comprehensive analysis of m6A related gene mutation characteristics and prognosis in colorectal cancer.
    Jiang T; Xing L; Zhao L; Ye Z; Yu D; Lin S
    BMC Med Genomics; 2023 May; 16(1):105. PubMed ID: 37194014
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of a Two-m6A RNA Methylation Regulator Risk Signature as an Independent Prognostic Biomarker in Papillary Renal Cell Carcinoma by Bioinformatic Analysis.
    Yang F; Zhao G; Ge L; Song Y; Hong K; Zhang H; Liu C; Hong P; Ma L
    Biomed Res Int; 2021; 2021():4582082. PubMed ID: 33628782
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stathmin 1 is highly expressed and associated with survival outcome in malignant adrenocortical tumours.
    Dos Santos Passaia B; Lima K; Kremer JL; da Conceição BB; de Paula Mariani BM; da Silva JCL; Zerbini MCN; Fragoso MCBV; Machado-Neto JA; Lotfi CFP
    Invest New Drugs; 2020 Jun; 38(3):899-908. PubMed ID: 31441020
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.